Literature DB >> 8963650

Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections.

U Schröder1, B A Sabel.   

Abstract

The Leu-enkephalin dalargin does not normally penetrate the blood brain barrier when given intravenously. Drug targeting to the brain was investigated by using poly(butylcyanoacrylate) nanoparticles which were coated with polysorbate 80. When injected intravenously in mice, dalargin-loaded nanoparticles coated with the polysorbate 80 induced an analgesic effect at doses of 5.0 mg/kg and 7.5 mg/kg dalargin as shown by hindlimb licking on the hot plate. Neither the intravenous injection of dalargin alone at various doses nor the mixture of dalargin-loaded nanoparticles without the polysorbate 80 were able to induce an analgesic activity. This confirms previous observations that nanoparticles provide a convenient method to deliver drugs across the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8963650     DOI: 10.1016/0006-8993(95)01375-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

1.  Toxicity of polymeric nanoparticles in vivo and in vitro.

Authors:  Nadine Voigt; Petra Henrich-Noack; Sarah Kockentiedt; Werner Hintz; Jürgen Tomas; Bernhard A Sabel
Journal:  J Nanopart Res       Date:  2014-05-06       Impact factor: 2.253

Review 2.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

3.  Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models.

Authors:  J Lode; I Fichtner; J Kreuter; A Berndt; J E Diederichs; R Reszka
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

Review 4.  Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.

Authors:  Sonu Bhaskar; Furong Tian; Tobias Stoeger; Wolfgang Kreyling; Jesús M de la Fuente; Valeria Grazú; Paul Borm; Giovani Estrada; Vasilis Ntziachristos; Daniel Razansky
Journal:  Part Fibre Toxicol       Date:  2010-03-03       Impact factor: 9.400

5.  Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects.

Authors:  Sutapa Barua; Samir Mitragotri
Journal:  Nano Today       Date:  2014-04-01       Impact factor: 20.722

6.  Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.

Authors:  Jörg Kreuter; Peter Ramge; Valery Petrov; Stefan Hamm; Svetlana E Gelperina; Britta Engelhardt; Renad Alyautdin; Hagen von Briesen; David J Begley
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

7.  Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.

Authors:  P Calvo; B Gouritin; H Chacun; D Desmaële; J D'Angelo; J P Noel; D Georgin; E Fattal; J P Andreux; P Couvreur
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

8.  Activity profiles of dalargin and its analogues in mu-, delta- and kappa-opioid receptor selective bioassays.

Authors:  N Pencheva; J Pospisek; L Hauzerova; T Barth; P Milanov
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

9.  Polybutylcyanoacrylate nanoparticles and drugs of the platinum family: last status.

Authors:  Dashti Rahmat Abadi Fatemeh; Hasan Ebrahimi Shahmabadi; Anita Abedi; Seyed Ebrahim Alavi; Fatemeh Movahedi; Maedeh Koohi Moftakhari Esfahani; Tahereh Zadeh Mehrizi; Azim Akbarzadeh
Journal:  Indian J Clin Biochem       Date:  2013-07-23

10.  OX26 modified hyperbranched polyglycerol-conjugated poly(lactic-co-glycolic acid) nanoparticles: synthesis, characterization and evaluation of its brain delivery ability.

Authors:  Hanmei Bao; Xu Jin; Ling Li; Feng Lv; Tianjun Liu
Journal:  J Mater Sci Mater Med       Date:  2012-05-09       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.